All patients had neuropathologically confirmed GBM with an expression of wild-type isocitrate dehydrogenase 1 (IDH-1) and wild-type ATRX and underwent resection of their tumor with 5-ALA guidance. The gene discussed is IDH1; the disease is glioblastoma.